You are here

  • Home
  • Archive
  • Volume 33, Issue Suppl 4
  • PR062/#686  First-in-human phase 1 study of torl-1–23, a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) in patients with ovarian cancer

Article metrics

Article menu

Download PDFPDF

Featured Posters: Poster Rounds with the Professors
AS11. Ovarian cancer
PR062/#686  First-in-human phase 1 study of torl-1–23, a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) in patients with ovarian cancer
Free

 

Online download statistics by month:

Online download statistics by month: November 2023 to December 2024

AbstractFullPdf
Nov 202379039
Dec 202361010
Jan 202464010
Feb 20244209
Mar 202491019
Apr 202479040
May 202435030
Jun 202447028
Jul 2024105041
Aug 202496046
Sep 2024109031
Oct 202463029
Nov 2024151042
Dec 202418011
Total10400385